These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 10677500)

  • 1. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.
    Li J; Sarosi I; Yan XQ; Morony S; Capparelli C; Tan HL; McCabe S; Elliott R; Scully S; Van G; Kaufman S; Juan SC; Sun Y; Tarpley J; Martin L; Christensen K; McCabe J; Kostenuik P; Hsu H; Fletcher F; Dunstan CR; Lacey DL; Boyle WJ
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1566-71. PubMed ID: 10677500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
    Burgess TL; Qian Y; Kaufman S; Ring BD; Van G; Capparelli C; Kelley M; Hsu H; Boyle WJ; Dunstan CR; Hu S; Lacey DL
    J Cell Biol; 1999 May; 145(3):527-38. PubMed ID: 10225954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis.
    Wada T; Nakashima T; Oliveira-dos-Santos AJ; Gasser J; Hara H; Schett G; Penninger JM
    Nat Med; 2005 Apr; 11(4):394-9. PubMed ID: 15750601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand.
    Xu J; Tan JW; Huang L; Gao XH; Laird R; Liu D; Wysocki S; Zheng MH
    J Bone Miner Res; 2000 Nov; 15(11):2178-86. PubMed ID: 11092398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.
    Hofbauer LC
    Eur J Endocrinol; 1999 Sep; 141(3):195-210. PubMed ID: 10474114
    [No Abstract]   [Full Text] [Related]  

  • 7. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
    Stajszczyk M
    Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.
    Xing L; Carlson L; Story B; Tai Z; Keng P; Siebenlist U; Boyce BF
    J Bone Miner Res; 2003 Feb; 18(2):260-9. PubMed ID: 12568403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
    Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL
    J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
    Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
    Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
    J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that the rat osteopetrotic mutation toothless (tl) is not in the TNFSF11 (TRANCE, RANKL, ODF, OPGL) gene.
    Odgren PR; Kim N; van Wesenbeeck L; MacKay C; Mason-Savas A; Safadi FF; Popoff SN; Lengner C; van-Hul W; Choi Y; Marks SC
    Int J Dev Biol; 2001 Dec; 45(8):853-9. PubMed ID: 11804028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
    Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
    Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.